{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:25Z","timestamp":1772165665647,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W021242\/1"],"award-info":[{"award-number":["MR\/W021242\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R024847\/1"],"award-info":[{"award-number":["MR\/R024847\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["NIHR200910"],"award-info":[{"award-number":["NIHR200910"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["NIHR200907"],"award-info":[{"award-number":["NIHR200907"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Our study examines if SARS-CoV-2 infections varied by vaccination status, if an individual had previously tested positive and by neighbourhood socioeconomic deprivation across the Delta and Omicron epidemic waves of SARS-CoV-2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Population cohort study using electronic health records for 2.7\u00a0M residents in Cheshire and Merseyside, England (3rd June 2021 to 1st March 2022). Our outcome variable was registered positive test for SARS-CoV-2. Explanatory variables were vaccination status, previous registered positive test and neighbourhood socioeconomic deprivation. Cox regression models were used to analyse associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Originally higher SARS-CoV-2 rates in the most socioeconomically deprived neighbourhoods changed to being higher in the least deprived neighbourhoods from the 1st September 2021, and were inconsistent during the Omicron wave. Individuals who were fully vaccinated (two doses) were associated with fewer registered positive tests (e.g., individuals engaged in testing between 1st September and 27th November 2021\u2014Hazards Ratio (HR)\u2009=\u20090.48, 95% Confidence Intervals (CIs)\u2009=\u20090.47\u20130.50. Individuals with a previous registered positive test were also less likely to have a registered positive test (e.g., individuals engaged in testing between 1st September and 27th November 2021\u2014HR\u2009=\u20090.16, 95% CIs\u2009=\u20090.15\u20130.18. However, the Omicron period saw smaller effect sizes for both vaccination status and previous registered positive test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Changing patterns of SARS-CoV-2 infections during the Delta and Omicron waves reveals a dynamic pandemic that continues to affect diverse communities in sometimes unexpected ways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-022-07878-2","type":"journal-article","created":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T20:19:13Z","timestamp":1669493953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Changing patterns of SARS-CoV-2 infection through Delta and Omicron waves by vaccination status, previous infection and neighbourhood deprivation: a cohort analysis of 2.7\u00a0M people"],"prefix":"10.1186","volume":"22","author":[{"given":"Mark A.","family":"Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Hungerford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Garcia-Fi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance","family":"Turtle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Cheyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Leeming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm G.","family":"Semple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Singleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain","family":"Buchan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,26]]},"reference":[{"issue":"10","key":"7878_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","volume":"21","author":"JS Tregoning","year":"2021","unstructured":"Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626\u201336.","journal-title":"Nat Rev Immunol"},{"issue":"54","key":"7878_CR2","doi-asserted-by":"publisher","first-page":"eabf8891","DOI":"10.1126\/sciimmunol.abf8891","volume":"5","author":"G Hartley","year":"2020","unstructured":"Hartley G, Edwards E, Aui P, Varese N, Stojanovic S, McMahon J, et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol. 2020;5(54):eabf8891.","journal-title":"Sci Immunol."},{"key":"7878_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12879-022-07239-z","volume":"22","author":"K Pattni","year":"2022","unstructured":"Pattni K, Hungerford D, Adams S, Buchan I, Cheyne CP, Garc\u00eda-Fi\u00f1ana M, et al. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2. BMC Infect Dis. 2022;22:270.","journal-title":"BMC Infect Dis"},{"issue":"10332","key":"7878_CR4","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","volume":"399","author":"T Nyberg","year":"2022","unstructured":"Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303\u201312.","journal-title":"Lancet"},{"key":"7878_CR5","unstructured":"ONS. Deaths involving COVID-19 by vaccination status, England: deaths occurring between 2 January and 24 September 2021 [Internet]. 2021. Available from: https:\/\/www.ons.gov.uk\/releases\/deathsinvolvingcovid19byvaccinationstatusenglanddeathsoccurringbetween2januaryand24september2021."},{"key":"7878_CR6","doi-asserted-by":"crossref","unstructured":"Baraniuk C. How long does covid-19 immunity last? BMJ. 2021;373.","DOI":"10.1136\/bmj.n1605"},{"issue":"24","key":"7878_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114228","volume":"385","author":"Y Goldberg","year":"2021","unstructured":"Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24): e85.","journal-title":"N Engl J Med"},{"key":"7878_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","volume":"386","author":"V Hall","year":"2022","unstructured":"Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med. 2022;386:1207\u201320.","journal-title":"N Engl J Med"},{"issue":"10321","key":"7878_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(21)02844-0","volume":"399","author":"W Dejnirattisai","year":"2022","unstructured":"Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart ASV, Pollard AJ, et al. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum. Lancet. 2022;399(10321):234\u20136.","journal-title":"Lancet"},{"issue":"10316","key":"7878_CR10","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","volume":"398","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Cohen C, Hern\u00e1n MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093\u2013100.","journal-title":"Lancet"},{"issue":"5","key":"7878_CR11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41562-020-0887-9","volume":"4","author":"R West","year":"2020","unstructured":"West R, Michie S, Rubin GJ, Aml\u00f4t R. Applying principles of behaviour change to reduce SARS-CoV-2 transmission. Nat Hum Behav. 2020;4(5):451\u20139.","journal-title":"Nat Hum Behav"},{"issue":"11","key":"7878_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240399","volume":"15","author":"LE Smith","year":"2020","unstructured":"Smith LE, Mottershaw AL, Egan M, Waller J, Marteau TM, Rubin GJ. The impact of believing you have had COVID-19 on self-reported behaviour: cross-sectional survey. PLoS ONE. 2020;15(11): e0240399.","journal-title":"PLoS ONE"},{"key":"7878_CR13","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268818003540","volume":"147","author":"TN Vilches","year":"2019","unstructured":"Vilches TN, Jaberi-Douraki M, Moghadas SM. Risk of influenza infection with low vaccine effectiveness: the role of avoidance behaviour. Epidemiol Infect. 2019;147: e75.","journal-title":"Epidemiol Infect"},{"key":"7878_CR14","unstructured":"Suleman M, Sonthalia S, Webb C, Tinson A, Kane M, Bunbury S, et al. Unequal pandemic, fairer recovery [Internet]. 2021. Available from: https:\/\/www.health.org.uk\/publications\/reports\/unequal-pandemic-fairer-recovery."},{"key":"7878_CR15","unstructured":"UK Government. Final report on progress to address COVID-19 health inequalities [Internet]. 2021. Available from: https:\/\/www.gov.uk\/government\/publications\/final-report-on-progress-to-address-covid-19-health-inequalities."},{"key":"7878_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114413","volume":"289","author":"K Morrissey","year":"2021","unstructured":"Morrissey K, Spooner F, Salter J, Shaddick G. Area level deprivation and monthly COVID-19 cases: the impact of government policy in England. Soc Sci Med. 2021;289: 114413.","journal-title":"Soc Sci Med"},{"key":"7878_CR17","unstructured":"ONS. COVID-19 vaccination rates and odds ratios by socio-demographic group [Internet]. 2021. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/healthinequalities\/datasets\/covid19vaccinationratesandoddsratiosbysociodemographicgroup."},{"key":"7878_CR18","unstructured":"UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England [Internet]. 2022. Available from: https:\/\/www.gov.uk\/government\/publications\/investigation-of-sars-cov-2-variants-technical-briefings."},{"key":"7878_CR19","unstructured":"Public Health England. Confirmed cases of COVID-19 variants identified in UK. 2021; Available from: https:\/\/www.gov.uk\/government\/news\/confirmed-cases-of-covid-19-variants-identified-in-uk."},{"key":"7878_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.21037\/atm.2018.02.12","volume":"6","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM. Time-varying covariates and coefficients in Cox regression models. Ann Transl Med. 2018;6:121.","journal-title":"Ann Transl Med."},{"issue":"10283","key":"7878_CR21","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(21)00675-9","volume":"397","author":"VJ Hall","year":"2021","unstructured":"Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397(10283):1459\u201369.","journal-title":"Lancet"},{"key":"7878_CR22","unstructured":"Ministry of Housing Communities and Local Government. The English Indices of Deprivation 2019 [Internet]. 2019. Available from: https:\/\/www.gov.uk\/government\/statistics\/english-indices-of-deprivation-2019."},{"issue":"15","key":"7878_CR23","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1056\/NEJMe2113151","volume":"385","author":"NE Dean","year":"2021","unstructured":"Dean NE, Hogan JW, Schnitzer ME. Covid-19 vaccine effectiveness and the test-negative design. N Engl J Med. 2021;385(15):1431\u20133.","journal-title":"N Engl J Med"},{"issue":"48","key":"7878_CR24","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.1016\/j.vaccine.2013.07.006","volume":"31","author":"G Hanquet","year":"2013","unstructured":"Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine [Internet]. 2013;31(48):5634\u201342.","journal-title":"Vaccine [Internet]."},{"key":"7878_CR25","doi-asserted-by":"crossref","unstructured":"Hughes DM, Bird SM, Cheyne CP, Ashton M, Campbell MC, Garc\u00eda-Fi\u00f1ana M, et al. Rapid antigen testing in COVID-19 management for school-aged children: an observational study in Cheshire and Merseyside, UK. J Public Health (Bangkok). 2022;fdac003.","DOI":"10.1093\/pubmed\/fdac003"},{"key":"7878_CR26","doi-asserted-by":"crossref","unstructured":"Buckell J, Jones J, Matthews PC, Diamond SI, Rourke E, Studley R, et al. COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK. medRxiv [Internet]. 2021; Available from: http:\/\/medrxiv.org\/content\/early\/2021\/11\/16\/2021.11.15.21266255.abstract.","DOI":"10.1101\/2021.11.15.21266255"},{"issue":"16","key":"7878_CR27","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B11529) variant. N Engl J Med. 2022;386(16):1532\u201346.","journal-title":"N Engl J Med"},{"key":"7878_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41579-022-00708-x","volume":"20","author":"E Simon-Loriere","year":"2022","unstructured":"Simon-Loriere E, Schwartz O. Towards SARS-CoV-2 serotypes? Nat Rev Microbiol. 2022;20:187\u20138.","journal-title":"Nat Rev Microbiol"},{"key":"7878_CR29","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1068\/a3692","volume":"35","author":"D Dorling","year":"2003","unstructured":"Dorling D, Rees P. A nation still dividing: the British census and social polarisation 1971\u20132001. Environ Plan A. 2003;35:1287\u2013313.","journal-title":"Environ Plan A"},{"issue":"1","key":"7878_CR30","first-page":"131","volume":"46","author":"S Gorard","year":"2016","unstructured":"Gorard S. The complex determinants of school intake characteristics and segregation, England 1989 to 2014, Cambridge. J Educ. 2016;46(1):131\u201346.","journal-title":"J Educ"},{"key":"7878_CR31","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.22.21265371v1","author":"J Bridgen","year":"2021","unstructured":"Bridgen J, Jewell C, Read J. Social mixing patterns in the UK following the relaxation of COVID-19 pandemic restrictions: a cross-sectional online survey. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.10.22.21265371v1.","journal-title":"medRxiv"},{"key":"7878_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100107","volume":"6","author":"MA Green","year":"2021","unstructured":"Green MA, Garcia-Fi\u00f1ana M, Barr B, Burnside G, Cheyne CP, Hughes D, et al. Evaluating social and spatial inequalities of large scale rapid lateral flow SARS-CoV-2 antigen testing in COVID-19 management: an observational study of Liverpool, UK (November 2020 to January 2021). Lancet Reg Heal Eur. 2021;6: 100107.","journal-title":"Lancet Reg Heal Eur"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07878-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07878-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07878-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T20:19:31Z","timestamp":1669493971000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07878-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,26]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7878"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07878-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.04.05.22273169","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,26]]},"assertion":[{"value":"27 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was granted by the University of Liverpool\u2019s Research Ethics committee (REF: 10634). Data access was granted by the CIPHA Information Governance panel and Liverpool Clinical Commissioning Group as part of the COVID-19 response work the team were involved in. All data accessed were pseudo-anonymised prior to use.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IB declares grants from NIHR, personal fees and other from AstraZeneca, outside the submitted work. MGS declares non-remunerated participation on Pfizer\u2019s External Data Monitoring Committee for their mRNA vaccine programmes. MGS holds stocks in Integrum Scientific LLC and MedEx Solutions Ltd. MGS also declares being a non-remunerated independent member of the UK Government\u2019s SAGE and NERVTAG groups. No further conflicts of interest are declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"889"}}